Integrative Review of Managed Entry Agreements: Chances and Limitations.
Carolina Zampirolli DiasBrian B GodmanLudmila Peres GarganoPâmela Santos AzevedoMarina Morgado GarciaMaurílio de Souza CazarimLaís Lessa Neiva PantuzzaNelio Gomes Ribeiro-JuniorAndré Luiz PereiraMarcus Carvalho BorinIsabella de Figueiredo ZuppoRoberto IunesTomas PippoRenata Curi HauegenCarlos VassaloTracey-Lea LabaSteven R A SimoensSergio MárquezCarolina GomezLuka VoncinaGisbert W SelkeLivio GarattiniHye-Young KwonJolanta GulbinovicAneta LipinskaMaciej PomorskiLindsay McClureJurij FürstRosana GambogiCarla Hernandez OrtizVânia Cristina Canuto SantosDenizar Vianna AraújoVânia Eloisa de AraújoFrancisco de Assis AcurcioJuliana Álvares TeodoroAugusto Afonso Guerra JuniorPublished in: PharmacoEconomics (2021)
We are likely to see a growth in MEAs with the continual launch of new high-priced and often complex treatments, coupled with increasing demands on resources. Whilst outcome-based MEAs could be an important tool to improve access to new innovative medicines, there are critical issues to address. Comparing knowledge, experiences, and practices across countries is crucial to guide high- and middle-income countries when designing their future MEAs.